Role of Being Public: Going public in the
Ethical Communication and Due Diligence:
Drug Development Milestones and Patient Access: The company's main objective is to make their drug accessible to as many patients as possible, prioritizing patient impact over company success, reflecting a patient-centric approach to healthcare.
Science-Based Differentiation and Market Opportunity: The guest emphasizes prior human experience with the drug, safety, and efficacy, and its differentiation in the oncology market, identifying a strong scientific foundation for competitive advantage.
The show, entitled, 'Your Advantage Play, In Search of the Ultimate Competitive Advantage,' has been on the air for 5 years with over 185 episodes released. It has been rated in the top 5% of all podcasts worldwide and featured CEOs of several public companies as well as some of the most highly regarded advisory talent in the country. It targets senior executives of middle market companies (generally
About
The Company's novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body's primary defense against cancer.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the planned studies and market projections described above and the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements because of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary business partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the
Contact:
Email: irteam@propanc.com
Tel: +61-3-9882-0780
(C) 2024 Electronic News Publishing, source